Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study

Table 2

Influence of CAD on plasma levels of MMP-2, MMP-9, and TIMP-4.

	CAD	Control	value	CAD + HT − DM−	Control	value	CCSII	CCSIII	value
MMP-2 (ng/ml)	154.5 ± 51.0	165.7 ± 19.1	0.037	134.5 ± 23.2	165.7 ± 19.1	<0.001	154.0 ± 51.6	158.8 ± 49.6	0.77
MMP-9 (ng/ml)	46.4 ± 26.4	47.2 ± 22.3	0.91	47.6 ± 29.4	47.2 ± 22.3	0.97	45.5 ± 25.4	54.2 ± 34.8	0.71
TIMP-4 (pg/ml)	1621.9 ± 757.4	1153.2 ± 339.9	0.011	1733.0 ± 665.4	1153.2 ± 339.9	0.008	1631.8 ± 788.0	1546.1 ± 487.4	0.85

CAD: coronary artery disease; CAD + HT − DM−: group of patients suffering from coronary artery disease only; CCSII, CCSIII: Canadian Cardiac Society classification of coronary artery disease clinical status: stage II and stage III, respectively; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; TIMP-4: tissue inhibitor of metalloproteinases 4. Mean ± SEM. Statistical tests used: Mann–Whitney U test and unpaired t-test.